Amneal Announces New Biosciences Unit With Charles Lucarelli As President

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal today announced the creation of Amneal Biosciences, a wholly-owned subsidiary of Amneal Pharmaceuticals LLC (www.amneal.com). Amneal Biosciences will focus exclusively on the commercialization of high-barrier-to-entry generic and specialty pharmaceuticals such as injectables, oncologics and biosimilars to healthcare providers globally.

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.